Lysozyme-Chitosan Composition for Acanthamoeba Adhesion Inhibition

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing treatments for Acanthamoeba-induced inflammation, particularly in contact lens wearers, are limited to biguanide-based germicides, and there is a need for alternative compositions with strong anti-amoebic effects.

Innovation Solution

A pharmaceutical composition comprising a complex of lysozyme and chitosan, bound together, which is safe for use as a food additive, exhibits antiprotozoal and anti-adhesion effects against Acanthamoeba, inhibiting its adhesion and proliferation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If biguanide-based germicides are used to treat Acanthamoeba infection, then anti-amoebic effect is achieved, but the variety of available compositions is limited and patient burden is increased

Engineering Contradiction:

Improvevariety of compositionsVSAvoidanti-amoebic effect

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent combines lysozyme and chitosan into a complex formulation to create a new composite anti-amoebic composition. This composite approach expands the variety of effective compositions beyond traditional biguanide-based germicides, providing patients with more treatment options while maintaining reliable anti-amoebic activity through the synergistic interaction of the two components.

Inventive Principle:

Principle #40Composite materials

2Reliability

If conventional anti-amoebic compositions are used, then treatment effectiveness is maintained, but the safety profile and natural derivation are reduced

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidsafety profile

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent employs lysozyme and chitosan, which are naturally derived substances with established safety profiles and food additive approvals. These naturally-derived components replace conventional synthetic anti-amoebic agents, maintaining treatment effectiveness while improving the safety profile by eliminating concerns associated with synthetic chemicals and their potential side effects.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent changes the chemical composition parameters by formulating an anti-amoebic agent based on naturally derived lysozyme and chitosan rather than conventional synthetic compounds. This parameter change in the chemical origin and composition of the active ingredients maintains therapeutic effectiveness while enhancing safety through the use of food-grade, naturally-derived substances with well-understood pharmacokinetics and minimal toxicity.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If lysozyme and chitosan complex is used, then anti-adhesion and antiprotozoal effects are enhanced, but the complexity of formulation is increased

Engineering Contradiction:

Improveanti-adhesion and antiprotozoal effectsVSAvoidformulation complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent merges lysozyme and chitosan into a single complex formulation that simultaneously provides anti-adhesion and antiprotozoal activities. This combining approach enhances the overall reliability of the treatment by integrating multiple mechanisms of action into one composition, preventing both adhesion and proliferation of Acanthamoeba through the synergistic interaction of the two components.

Inventive Principle:

Principle #5Merging (Combining)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The lysozyme-chitosan complex effectively inhibits Acanthamoeba adhesion and proliferation, achieving significant lethal effects and reducing the burden on patients by using naturally-derived ingredients.

Implementation Method 1

the complex of lysozyme and chitosan bound together in the present invention not only inhibits the proliferation of Acanthamoeba but also exhibits significant lethal effects

Methodology Applied

Scientific EffectAdhesion inhibition: Adhesive

Implementation Method 2

the complex of lysozyme and chitosan bound together in the present invention not only inhibits the proliferation of Acanthamoeba but also exhibits significant lethal effects

Methodology Applied

Scientific EffectLethal effect:

Data Source

PatentUS20260027214A1Pharmaceutical composition for treating or preventing inflammation caused by acanthamoeba

Publication Date: 2026.01.29 WAKO FILTER TECH

AI summary

A pharmaceutical composition for treating or preventing inflammation caused by Acanthamoeba that contains a composite formed by joining lysozyme and chitosan is described. Also described are an antiprotozoal composition contains a composite formed by joining lysozyme and chitosan, an anti-attachment agent for Acanthamoeba that contains a composite formed by joining lysozyme and chitosan.